Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Mar;3(1):46-55.
doi: 10.1177/2048872613502283. Epub 2013 Sep 11.

The Seattle Post Myocardial Infarction Model (SPIM): prediction of mortality after acute myocardial infarction with left ventricular dysfunction

Eric S Ketchum  1 , Kenneth Dickstein, John Kjekshus, Bertram Pitt, Meagan F Wong, David T Linker, Wayne C Levy
Affiliations
Randomized Controlled Trial

The Seattle Post Myocardial Infarction Model (SPIM): prediction of mortality after acute myocardial infarction with left ventricular dysfunction

Eric S Ketchum et al. Eur Heart J Acute Cardiovasc Care. 2014 Mar.

Abstract

Aims: Ischemic heart disease is a leading worldwide cause of death. The Seattle Post Myocardial Infarction Model (SPIM) was developed to predict survival 6 months to 2 years after an acute myocardial infarction with evidence of left ventricular dysfunction.

Methods and results: A total of 6632 subjects from the EPHESUS trial were used to derive the predictive model, while 5477 subjects from the OPTIMAAL trial were used to validate the model. Cox proportional hazards modeling was used to develop a multivariate risk score predictive of all-cause mortality. The SPIM risk score integrated lab and vital parameters, Killip class, reperfusion or revascularization, the number of cardiac evidence-based medicines (aspirin, statin, β blocker, ACEI/ARB, aldosterone blocker), and the number of cardiac risk factors. The model was predictive of all-cause mortality after myocardial infarction, with an AUC of 0.75 at 6 months and 0.75 at 2 years in the derivation cohort and 0.77 and 0.78 for the same time points in the validation cohort. Model predicted versus Kaplan-Meier observed survival was excellent in the derivation cohort. It remained so in the validation cohort--84.9% versus 85.0% at 2 years. The 10% of subjects with the highest predicted risk had approximately 25 times higher mortality at 2 years than the 10% of subjects with the lowest predicted risk.

Conclusion: The SPIM score was a powerful predictor of outcomes after myocardial infarction with left ventricular dysfunction. Its highly accurate predictions should improve patient and physician understanding of survival and may prove a useful tool in post-infarct risk stratification.

Keywords: Myocardial infarction; risk model; survival.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: EPHESUS was funded by Pfizer and OPTIMAAL by Merck.

Wayne Levy has received funding from GlaxoSmithKline, Boehringer Ingelheim, and Amgen. Bertram Pitt has received funding from Pfizer, Merck, Novartis, Takeda, Bayer, AstraZeneca, Lilly, BMS, GE Healthcare, Relypsa, BG Medicine, Amorcyte, Cytopherx, Aura Sense, Ardelyx, Forrest Laboratories, and Medtronic.

Figures

Figure 1.
Figure 1.
Equally populated deciles of several clinical variables that showed strong univariate associations with 1 year Kaplan-Meier mortality in the derivation cohort plotted with the univariate hazard function.
Figure 2.
Figure 2.
Mortality curves for the derivation cohort based on number of evidence based medicines at baseline (a) and the number of risk factors (b). The number of patients is listed for each grouping. ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin II receptor blocker; ASA: aspirin; CHF: congestive heart failure; CVD: cerebrovascular disease; DM: diabetes mellitus.
Figure 3.
Figure 3.
Kaplan-Meier observed mortality for each decile of SPIM predicted mortality in the derivation (a) and validation (b) cohorts.
Figure 4.
Figure 4.
Comparison of deciles of SPIM predicted versus Kaplan-Meier observed survival at 1 and 2 years in the derivation (a) and validation (b) cohorts.
See this image and copyright information in PMC

References

    1. Krumholz HM, Wang Y, Chen J, et al. Reduction in acute myocardial infarction mortality in the United States: Risk-standardized mortality rates from 1995–2006. JAMA 2009; 302: 767–773 - PMC - PubMed
    1. Yeh RW, Sidney S, Chandra M, et al. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med 2010; 362: 2155–2165 - PubMed
    1. Puymirat E, Simon T, Steg PG, et al. Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction. JAMA 2012; 308: 998–1006 - PubMed
    1. Jernberg T, Johanson P, Held C, et al. Association between adoption of evidence-based treatment and survival for patients with ST-elevation myocardial infarction. JAMA 2011; 305: 1677–1684 - PubMed
    1. Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in U.S. deaths from coronary disease, 1980–2000. N Engl J Med 2007; 356: 2388–2398 - PubMed

Publication types

MeSH terms